What is the clinical evidence from this study?

Study design: RCT. Population: Obstructive sleep apnea (OSA) and untreated hypertension (n=36). Intervention: Mild intermittent hypoxia (MIH) vs. Sham with or without CPAP. Primary outcome: Change in 24-hour blood pressure at 4 weeks.

What does this research mean for the field?

Mild intermittent hypoxia for 3 weeks reduces blood pressure and improves microvascular function and exercise capacity in patients with obstructive sleep apnea, independent of CPAP usage. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to determine if mild intermittent hypoxia can reduce blood pressure, enhance microvascular function, and improve exercise capacity independently of CPAP treatment.

May 20, 2026

C100-08 Repeated Daily Exposure To Mild Intermittent Hypoxia Improves Blood Pressure, Microvascular Function, And Exercise Capacity In OSA Patients Independent Of CPAP Usage

Key Result

Mild intermittent hypoxia for 3 weeks reduced blood pressure (Δ -10.50 to -12.93 mmHg) and improved microvascular function and exercise capacity in OSA patients, independent of CPAP.

Key Points

The aim is to determine if mild intermittent hypoxia can reduce blood pressure, enhance microvascular function, and improve exercise capacity independently of CPAP treatment.
Participants were randomized into four groups: MIH + CPAP, sham + CPAP, MIH, and sham.
MIH group was exposed to twelve 2-minute episodes of mild intermittent hypoxia over 3 weeks.
24-hour blood pressure and microvascular function were measured before and after treatment at multiple time points.
Blood pressure reduction observed in both MIH groups sustained for 4 weeks (Group 1: -10.50 mmHg, Group 3: -12.93 mmHg).
Sustained increase in maximal hyperemic response noted for 4 weeks in MIH groups (Group 1: 580.31 a.u., Group 3: 692.93 a.u.).
Enhanced walking distance and oxygen consumption at anaerobic threshold sustained for 8 weeks post-treatment in MIH groups.

Study Design

Type

RCT (n=36)

Randomization

Randomized to one of four groups

Structured PICO

Does mild intermittent hypoxia improve blood pressure, microvascular function, and exercise capacity in patients with OSA and untreated hypertension?

Population

36 individuals living with obstructive sleep apnea (OSA) and untreated hypertension (32 male, 4 female).

Intervention

Mild intermittent hypoxia (MIH) consisting of twelve 2-minute episodes (PETO2 = 50 mmHg) 5 days/week over a 3-week period, with or without continuous positive airway pressure (CPAP).

Comparator

Sham exposure with or without continuous positive airway pressure (CPAP).

Outcome

24-hour blood pressure measured at 4 days, 4 weeks, and 8 weeks after treatment.surrogate

Mild intermittent hypoxia improves blood pressure, microvascular function, and exercise capacity in patients with OSA and untreated hypertension, independent of CPAP therapy.

Abstract

Abstract Rationale Exposure to fifteen days of mild intermittent hypoxia (MIH), combined with continuous positive airway pressure (CPAP) treatment, results in a significant reduction in resting blood pressure in individuals living with obstructive sleep apnea (OSA) and untreated hypertension. The present study was designed to explore if the reduction in blood pressure is sustained for up to 8 weeks and induced independent of CPAP treatment. The present investigation also explored if the reduction in blood pressure is coupled with improvements in microvascular function and exercise capacity. Methods Participants were randomized to one of four groups: Group 1 – MIH + CPAP (8M,1F), Group 2 – sham + CPAP (8M,1F), Group 3 - MIH (7M,1F), Group 4 - sham (9M,1F). Groups 1 and 3 were exposed to twelve 2-minute episodes of MIH (PETO2 = 50 mmHg) 5 days/week over a 3-week period. 24-hour blood pressure was measured before treatment, as well as, 4 days, 4 weeks, and 8 weeks after treatment. At the same time points, microvascular function was assessed using near infrared spectroscopy (NIRS). In addition, exercise capacity and fatigue were assessed utilizing a submaximal ten-minute walk test and a maximum oxygen consumption test. P 0.05 was statistically significant. Results A reduction in blood pressure that was sustained for 4 weeks was evident in all participants exposed to MIH (Δ from baseline Group 1: -10.50 ± 7.25 mmHg; Group 3: -12.93 ± 9.51 mmHg). This reduction was not evident in Groups 2 and 4. Likewise, an increase in the maximal hyperemic response was sustained for 4 weeks in Groups 1 and 3 (Δ from baseline Group1: 580.31 ± 593.21 a.u.; Group 3: 692.93 ± 519.76 a.u.) but was not evident in Groups 2 and 4. Treatment with MIH led to an increased ability to walk further compared to baseline for 4 weeks during submaximal exercise (Group 1: 109.07 ± 138.60 m; Group 3: 119.49 ± 131.99 m). An increase in oxygen consumption at the anaerobic threshold was sustained for eight weeks compared to both sham and baseline following MIH (Group 1: 1.48±0.99 mL/kg/min; Group 3: 2.38±1.86 mL/kg/min). The reduction in blood pressure was correlated with an increased ability to walk further during submaximal exercise (R2 = 0.647). Conclusions MIH treatment effectively improves blood pressure, microvascular function, and exercise capacity that is sustained for at least 4 weeks. The response to treatment occurs independent of treatment with CPAP. This abstract is funded by: United States Department of Veterans Affairs (I01CX000125; IK6CX002287); National Institute of Heart, Lung and Blood (R01HL085537)

KI fragen

Bookmark